. . . "N-Allylnoroxymorphone"@en . . . "EN 1530 Base"@en . . . . . . . "Humans and other mammals"@en . . "Following parenteral administration naloxone hydrochloride is rapidly distributed in the body. Naloxone is also very lipophillic and easily crosses the blood-brain-barrier. It can also cross the placenta. "@en . "LD50, IV administration, mouse = 150 \u00B1 5 mg/kg; LD50, IV administration, rat = 109 \u00B1 4 mg/kg; "@en . . "1-N-Allyl-14-hydroxynordihydromorphinone"@en . . "465-65-6"@en . "Naloxone"@en . "L-Naloxone"@en . . . . . . . "Well absorbed following intramuscular injection."@en . . . . . . . "Adults = 30-81 minutes; Neonates = 3.1 \u00B1 0.5 hours. "@en . . . . "# FDA label # http://www.medscape.com/viewarticle/441915_3"@en . "Naloxona"@en . . . . . . . . . . . . . "Nalossone"@en . . "Bianca Brogmann, Silke Muhlau, Christof Spitzley, \"Pharmaceutical preparation containing oxycodone and naloxone.\" U.S. Patent US20050245556, issued November 03, 2005."@en . . . . . . . . . "Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constituent but significant binding of naloxone also occurs to plasma constituents other than albumin."@en . . . . . . . . . . . . . . . . . . . . . . . . "For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock. "@en . "approved"@en . "Naloxonum"@en . "17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one"@en . "Urine (25%- 40% is excreted as metabolites within 6 hours) "@en . "A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]"@en . . . "While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor."@en . " "@en . . . . . . " "@en . "Naloxone"@en . . .